Home > Boards > US Listed > Biotechs > Cytori Therapeutics, Inc. (CYTX)

NEWS -- Cytori Announces New Annual Stockholders Meeting

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 64
Posts 9,906
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/16/2019 4:51:16 PM
Cytori Will Become Plus Therapeutics, Inc. GlobeNewswire Inc. - 7/16/2019 4:15:00 PM
Cytori to Present Corporate Update & New Strategic Direction GlobeNewswire Inc. - 7/11/2019 8:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/11/2019 5:26:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/5/2019 8:01:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2019 5:17:56 PM
Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product GlobeNewswire Inc. - 7/1/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/27/2019 5:21:09 PM
Cytori Announces New Annual Stockholders Meeting Date for July 11 GlobeNewswire Inc. - 6/27/2019 5:10:00 PM
Cytori Announces New Annual Stockholders Meeting Date for June 27 GlobeNewswire Inc. - 6/19/2019 1:15:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 8:02:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 8:02:08 AM
Cytori to Present New Strategic Direction GlobeNewswire Inc. - 6/13/2019 10:43:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/30/2019 4:32:29 PM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/30/2019 4:18:10 PM
Cytori Announces New Annual Stockholders Meeting Date for June 18 GlobeNewswire Inc. - 5/30/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2019 4:58:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 4:52:10 PM
Cytori Reports Q1 2019 Business and Financial Results GlobeNewswire Inc. - 5/14/2019 4:50:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2019 8:02:41 AM
Japan Cell Therapy Transaction Yields $3MM GlobeNewswire Inc. - 4/23/2019 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 6:03:34 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/19/2019 6:02:47 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/5/2019 5:32:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 8:11:50 AM
Paulness   Thursday, 05/30/19 04:32:56 PM
Re: None
Post # of 2706 
NEWS -- Cytori Announces New Annual Stockholders Meeting Date for June 18

Today : Thursday 30 May 2019

Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it convened its annual meeting of stockholders on Tuesday, May 28, 2019 and adjourned the meeting until Tuesday, June 18, 2019, at 9:00 a.m., Pacific Time. The annual meeting was adjourned to allow the Company’s stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company’s common stock. Although more than 64% of the votes cast were in favor of the reverse stock split (Proposal 4), approval requires the affirmative vote of a majority of the outstanding shares of common stock.

The annual meeting was adjourned until 9:00 a.m., Pacific Time, on June 18, 2019 at 3020 Callan Road, San Diego, California 92121, the Company’s headquarters and the original location of the annual meeting. The record date for the annual meeting remains March 29, 2019. Stockholders that have yet to vote are requested to do so prior to the new June 18 meeting date and are encouraged to vote in favor of the reverse stock split as outlined in the Company’s proxy materials.

Stockholders who have previously sent in proxy cards or given instructions to brokers do not need to re-cast their votes unless they want to change their vote. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked.

If stockholders have questions, need help voting shares, or want to change a vote in favor of Proposal 4, please call the voting center at (289) 695-3947.

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs. Cytori is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents or other drugs which may enable the effective delivery of the agents to target sites while reducing systemic toxicity and improving pharamacokinetics. Cytori’s pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. For more information, please visit ir.cytori.com.

Cytori Therapeutics, Inc.

Gary Titus, +1 (858) 458.0900
mailto://ir@cytori.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist